D
Neogenomics, Inc.
NEO
$10.10
-$0.44-4.18%
D
Sell
1/12/2024Upgraded
Neogenomics, Inc. (NEO) was upgraded to D- from E+ on 1/12/2024 due to an increase in the valuation index and volatility index.
Neogenomics, Inc. (NEO) was upgraded to D- from E+ on 1/12/2024 due to an increase in the valuation index and volatility index.
E
Sell
12/28/2023Downgrade
Neogenomics, Inc. (NEO) was downgraded to E+ from D- on 12/28/2023 due to a decline in the volatility index and valuation index.
Neogenomics, Inc. (NEO) was downgraded to E+ from D- on 12/28/2023 due to a decline in the volatility index and valuation index.
D
Sell
12/8/2023Upgraded
Neogenomics, Inc. (NEO) was upgraded to D- from E+ on 12/8/2023 due to an increase in the total return index and volatility index.
Neogenomics, Inc. (NEO) was upgraded to D- from E+ on 12/8/2023 due to an increase in the total return index and volatility index.
E
Sell
11/21/2023Downgrade
Neogenomics, Inc. (NEO) was downgraded to E+ from D- on 11/21/2023 due to a decline in the volatility index and valuation index.
Neogenomics, Inc. (NEO) was downgraded to E+ from D- on 11/21/2023 due to a decline in the volatility index and valuation index.
D
Sell
3/14/2023Downgrade
Neogenomics, Inc. (NEO) was downgraded to D- from D on 3/14/2023 due to a substantial decline in the efficiency index and valuation index. Total capital declined 0.96% from $1.62B to $1.61B.
Neogenomics, Inc. (NEO) was downgraded to D- from D on 3/14/2023 due to a substantial decline in the efficiency index and valuation index. Total capital declined 0.96% from $1.62B to $1.61B.
D
Sell
8/12/2022Upgraded
Neogenomics, Inc. (NEO) was upgraded to D from D- on 8/12/2022 due to a substantial increase in the efficiency index and valuation index. Net income increased 28.55% from -$49.41M to -$35.3M.
Neogenomics, Inc. (NEO) was upgraded to D from D- on 8/12/2022 due to a substantial increase in the efficiency index and valuation index. Net income increased 28.55% from -$49.41M to -$35.3M.
D
Sell
5/31/2022Upgraded
Neogenomics, Inc. (NEO) was upgraded to D- from E+ on 5/31/2022 due to an increase in the valuation index.
Neogenomics, Inc. (NEO) was upgraded to D- from E+ on 5/31/2022 due to an increase in the valuation index.
E
Sell
5/13/2022Downgrade
Neogenomics, Inc. (NEO) was downgraded to E+ from D- on 5/13/2022 due to a decline in the total return index and volatility index.
Neogenomics, Inc. (NEO) was downgraded to E+ from D- on 5/13/2022 due to a decline in the total return index and volatility index.
D
Sell
5/10/2022Downgrade
Neogenomics, Inc. (NEO) was downgraded to D- from D on 5/10/2022 due to a significant decline in the efficiency index, total return index and solvency index. Net income declined 18.32% from -$41.76M to -$49.41M, debt to equity increased from 0.49 to 0.5, and total capital declined 1.91% from $1.72B to $1.69B.
Neogenomics, Inc. (NEO) was downgraded to D- from D on 5/10/2022 due to a significant decline in the efficiency index, total return index and solvency index. Net income declined 18.32% from -$41.76M to -$49.41M, debt to equity increased from 0.49 to 0.5, and total capital declined 1.91% from $1.72B to $1.69B.
D
Sell
3/2/2022Downgrade
Neogenomics, Inc. (NEO) was downgraded to D from C- on 3/2/2022 due to a noticeable decline in the efficiency index, valuation index and total return index. Net income declined 105.22% from -$20.35M to -$41.76M, and total capital declined 1.65% from $1.75B to $1.72B.
Neogenomics, Inc. (NEO) was downgraded to D from C- on 3/2/2022 due to a noticeable decline in the efficiency index, valuation index and total return index. Net income declined 105.22% from -$20.35M to -$41.76M, and total capital declined 1.65% from $1.75B to $1.72B.
C
Hold
2/17/2022Upgraded
Neogenomics, Inc. (NEO) was upgraded to C- from D+ on 2/17/2022 due to a noticeable increase in the valuation index and efficiency index.
Neogenomics, Inc. (NEO) was upgraded to C- from D+ on 2/17/2022 due to a noticeable increase in the valuation index and efficiency index.
D
Sell
11/8/2021Downgrade
Neogenomics, Inc. (NEO) was downgraded to D+ from C on 11/8/2021 due to a significant decline in the growth index, solvency index and efficiency index. Operating cash flow declined 458.78% from -$1.39M to -$7.77M, EBIT declined 235.83% from -$11.37M to -$38.18M, and earnings per share declined from $0.59 to -$0.17.
Neogenomics, Inc. (NEO) was downgraded to D+ from C on 11/8/2021 due to a significant decline in the growth index, solvency index and efficiency index. Operating cash flow declined 458.78% from -$1.39M to -$7.77M, EBIT declined 235.83% from -$11.37M to -$38.18M, and earnings per share declined from $0.59 to -$0.17.
C
Hold
8/11/2021Upgraded
Neogenomics, Inc. (NEO) was upgraded to C from D on 8/11/2021 due to a significant increase in the growth index, efficiency index and valuation index. Net income increased 443.1% from -$22.11M to $75.87M, earnings per share increased from -$0.1903 to $0.59, and total capital increased 21.61% from $1.43B to $1.74B.
Neogenomics, Inc. (NEO) was upgraded to C from D on 8/11/2021 due to a significant increase in the growth index, efficiency index and valuation index. Net income increased 443.1% from -$22.11M to $75.87M, earnings per share increased from -$0.1903 to $0.59, and total capital increased 21.61% from $1.43B to $1.74B.
D
Sell
6/10/2021Downgrade
Neogenomics, Inc. (NEO) was downgraded to D from D+ on 6/10/2021 due to a decline in the volatility index and total return index.
Neogenomics, Inc. (NEO) was downgraded to D from D+ on 6/10/2021 due to a decline in the volatility index and total return index.
D
Sell
5/11/2021Downgrade
Neogenomics, Inc. (NEO) was downgraded to D+ from C- on 5/11/2021 due to a noticeable decline in the growth index, efficiency index and total return index. Net income declined 243.44% from $15.42M to -$22.11M, earnings per share declined from $0.1333 to -$0.1903, and EBIT declined 234.93% from $5.76M to -$7.77M.
Neogenomics, Inc. (NEO) was downgraded to D+ from C- on 5/11/2021 due to a noticeable decline in the growth index, efficiency index and total return index. Net income declined 243.44% from $15.42M to -$22.11M, earnings per share declined from $0.1333 to -$0.1903, and EBIT declined 234.93% from $5.76M to -$7.77M.
C
Hold
4/22/2021Upgraded
Neogenomics, Inc. (NEO) was upgraded to C- from D+ on 4/22/2021 due to an increase in the volatility index.
Neogenomics, Inc. (NEO) was upgraded to C- from D+ on 4/22/2021 due to an increase in the volatility index.
D
Sell
3/12/2021Downgrade
Neogenomics, Inc. (NEO) was downgraded to D+ from C- on 3/12/2021 due to a large decline in the total return index and volatility index.
Neogenomics, Inc. (NEO) was downgraded to D+ from C- on 3/12/2021 due to a large decline in the total return index and volatility index.
C
Hold
3/9/2021Downgrade
Neogenomics, Inc. (NEO) was downgraded to C- from C on 3/9/2021 due to a major decline in the total return index.
Neogenomics, Inc. (NEO) was downgraded to C- from C on 3/9/2021 due to a major decline in the total return index.
C
Hold
2/12/2021Upgraded
Neogenomics, Inc. (NEO) was upgraded to C from C- on 2/12/2021 due to an increase in the total return index, volatility index and efficiency index. Net income increased 137.47% from -$6.82M to $2.56M, and total capital increased 1.32% from $874.16M to $885.73M.
Neogenomics, Inc. (NEO) was upgraded to C from C- on 2/12/2021 due to an increase in the total return index, volatility index and efficiency index. Net income increased 137.47% from -$6.82M to $2.56M, and total capital increased 1.32% from $874.16M to $885.73M.
C
Hold
10/14/2020Upgraded
Neogenomics, Inc. (NEO) was upgraded to C- from D+ on 10/14/2020 due to a large increase in the total return index and volatility index.
Neogenomics, Inc. (NEO) was upgraded to C- from D+ on 10/14/2020 due to a large increase in the total return index and volatility index.
D
Sell
9/29/2020Downgrade
Neogenomics, Inc. (NEO) was downgraded to D+ from C- on 9/29/2020 due to a large decline in the total return index.
Neogenomics, Inc. (NEO) was downgraded to D+ from C- on 9/29/2020 due to a large decline in the total return index.
C
Hold
9/9/2020Upgraded
Neogenomics, Inc. (NEO) was upgraded to C- from D+ on 9/9/2020 due to a large increase in the total return index.
Neogenomics, Inc. (NEO) was upgraded to C- from D+ on 9/9/2020 due to a large increase in the total return index.
D
Sell
8/21/2020Downgrade
Neogenomics, Inc. (NEO) was downgraded to D+ from C- on 8/21/2020 due to a noticeable decline in the total return index and solvency index.
Neogenomics, Inc. (NEO) was downgraded to D+ from C- on 8/21/2020 due to a noticeable decline in the total return index and solvency index.
C
Hold
8/5/2020Upgraded
Neogenomics, Inc. (NEO) was upgraded to C- from D+ on 8/5/2020 due to a large increase in the total return index and solvency index. The quick ratio increased from 2.77 to 6.23.
Neogenomics, Inc. (NEO) was upgraded to C- from D+ on 8/5/2020 due to a large increase in the total return index and solvency index. The quick ratio increased from 2.77 to 6.23.
D
Sell
5/11/2020Downgrade
Neogenomics, Inc. (NEO) was downgraded to D+ from C- on 5/11/2020 due to a decline in the total return index.
Neogenomics, Inc. (NEO) was downgraded to D+ from C- on 5/11/2020 due to a decline in the total return index.
C
Hold
4/30/2020Downgrade
Neogenomics, Inc. (NEO) was downgraded to C- from C on 4/30/2020 due to a major decline in the growth index, total return index and volatility index. Operating cash flow declined 306.4% from $3.36M to -$6.93M, earnings per share declined from $0.0578 to -$0.07, and EBIT declined 218.5% from $3.37M to -$4M.
Neogenomics, Inc. (NEO) was downgraded to C- from C on 4/30/2020 due to a major decline in the growth index, total return index and volatility index. Operating cash flow declined 306.4% from $3.36M to -$6.93M, earnings per share declined from $0.0578 to -$0.07, and EBIT declined 218.5% from $3.37M to -$4M.
C
Hold
3/3/2020Upgraded
Neogenomics, Inc. (NEO) was upgraded to C from C- on 3/3/2020 due to a substantial increase in the growth index, total return index and efficiency index. Net income increased 193.79% from $2.14M to $6.3M, earnings per share increased from $0.02 to $0.0578, and total revenue increased 2.1% from $104.67M to $106.87M.
Neogenomics, Inc. (NEO) was upgraded to C from C- on 3/3/2020 due to a substantial increase in the growth index, total return index and efficiency index. Net income increased 193.79% from $2.14M to $6.3M, earnings per share increased from $0.02 to $0.0578, and total revenue increased 2.1% from $104.67M to $106.87M.
C
Hold
1/10/2020Upgraded
Neogenomics, Inc. (NEO) was upgraded to C- from D+ on 1/10/2020 due to a noticeable increase in the total return index, volatility index and solvency index.
Neogenomics, Inc. (NEO) was upgraded to C- from D+ on 1/10/2020 due to a noticeable increase in the total return index, volatility index and solvency index.
D
Sell
11/14/2019Downgrade
Neogenomics, Inc. (NEO) was downgraded to D+ from C- on 11/14/2019 due to a significant decline in the growth index, total return index and valuation index. EBIT declined 19.98% from $4.99M to $3.99M.
Neogenomics, Inc. (NEO) was downgraded to D+ from C- on 11/14/2019 due to a significant decline in the growth index, total return index and valuation index. EBIT declined 19.98% from $4.99M to $3.99M.
C
Hold
10/8/2019Downgrade
Neogenomics, Inc. (NEO) was downgraded to C- from C on 10/8/2019 due to a substantial decline in the total return index.
Neogenomics, Inc. (NEO) was downgraded to C- from C on 10/8/2019 due to a substantial decline in the total return index.
C
Hold
8/13/2019Upgraded
Neogenomics, Inc. (NEO) was upgraded to C from C- on 8/13/2019 due to a substantial increase in the growth index, solvency index and efficiency index. The quick ratio increased from 1.32 to 4.35, net income increased 182.14% from -$2.42M to $1.99M, and earnings per share increased from -$0.03 to $0.02.
Neogenomics, Inc. (NEO) was upgraded to C from C- on 8/13/2019 due to a substantial increase in the growth index, solvency index and efficiency index. The quick ratio increased from 1.32 to 4.35, net income increased 182.14% from -$2.42M to $1.99M, and earnings per share increased from -$0.03 to $0.02.
C
Hold
7/12/2019Downgrade
Neogenomics, Inc. (NEO) was downgraded to C- from C on 7/12/2019 due to a decline in the efficiency index, volatility index and valuation index. Net income declined 786.69% from $353 to -$2.42M.
Neogenomics, Inc. (NEO) was downgraded to C- from C on 7/12/2019 due to a decline in the efficiency index, volatility index and valuation index. Net income declined 786.69% from $353 to -$2.42M.
C
Hold
3/29/2019Upgraded
Neogenomics, Inc. (NEO) was upgraded to C from C- on 3/29/2019 due to an increase in the solvency index, total return index and volatility index. Debt to equity declined from 0.34 to 0.33.
Neogenomics, Inc. (NEO) was upgraded to C from C- on 3/29/2019 due to an increase in the solvency index, total return index and volatility index. Debt to equity declined from 0.34 to 0.33.
C
Hold
11/8/2018Downgrade
Neogenomics, Inc. (NEO) was downgraded to C- from C on 11/8/2018 due to a substantial decline in the growth index. Earnings per share declined from $0.07 to $0.02.
Neogenomics, Inc. (NEO) was downgraded to C- from C on 11/8/2018 due to a substantial decline in the growth index. Earnings per share declined from $0.07 to $0.02.
C
Hold
5/25/2018Upgraded
Neogenomics, Inc. (NEO) was upgraded to C from C- on 5/25/2018 due to a substantial increase in the total return index, growth index and efficiency index. Operating cash flow increased 148.52% from $5.76M to $14.31M.
Neogenomics, Inc. (NEO) was upgraded to C from C- on 5/25/2018 due to a substantial increase in the total return index, growth index and efficiency index. Operating cash flow increased 148.52% from $5.76M to $14.31M.
C
Hold
3/16/2018Upgraded
Neogenomics, Inc. (NEO) was upgraded to C- from D+ on 3/16/2018 due to a large increase in the growth index, solvency index and efficiency index. EBIT increased 294.75% from -$2.3M to $4.49M, net income increased 197.08% from -$5.1M to $4.95M, and earnings per share increased from -$0.1 to $0.0261.
Neogenomics, Inc. (NEO) was upgraded to C- from D+ on 3/16/2018 due to a large increase in the growth index, solvency index and efficiency index. EBIT increased 294.75% from -$2.3M to $4.49M, net income increased 197.08% from -$5.1M to $4.95M, and earnings per share increased from -$0.1 to $0.0261.
D
Sell
11/22/2017Downgrade
Neogenomics, Inc. (NEO) was downgraded to D+ from C- on 11/22/2017 due to a noticeable decline in the total return index, efficiency index and valuation index. Net income declined 11,760.47% from -$43 to -$5.1M, and total capital declined 0.38% from $305.88M to $304.72M.
Neogenomics, Inc. (NEO) was downgraded to D+ from C- on 11/22/2017 due to a noticeable decline in the total return index, efficiency index and valuation index. Net income declined 11,760.47% from -$43 to -$5.1M, and total capital declined 0.38% from $305.88M to $304.72M.
C
Hold
10/31/2017Downgrade
Neogenomics, Inc. (NEO) was downgraded to C- from C on 10/31/2017 due to a major decline in the total return index.
Neogenomics, Inc. (NEO) was downgraded to C- from C on 10/31/2017 due to a major decline in the total return index.
C
Hold
10/16/2017Upgraded
Neogenomics, Inc. (NEO) was upgraded to C from C- on 10/16/2017 due to a substantial increase in the total return index and volatility index.
Neogenomics, Inc. (NEO) was upgraded to C from C- on 10/16/2017 due to a substantial increase in the total return index and volatility index.
C
Hold
8/16/2017Upgraded
Neogenomics, Inc. (NEO) was upgraded to C- from D+ on 8/16/2017 due to a noticeable increase in the total return index.
Neogenomics, Inc. (NEO) was upgraded to C- from D+ on 8/16/2017 due to a noticeable increase in the total return index.
D
Sell
3/15/2017Downgrade
Neogenomics, Inc. (NEO) was downgraded to D+ from C- on 3/15/2017 due to a large decline in the total return index, growth index and solvency index. Earnings per share declined from -$0.0721 to -$0.1809, debt to equity increased from 0.29 to 0.62, and operating cash flow declined 102.5% from $9.62M to -$241.
Neogenomics, Inc. (NEO) was downgraded to D+ from C- on 3/15/2017 due to a large decline in the total return index, growth index and solvency index. Earnings per share declined from -$0.0721 to -$0.1809, debt to equity increased from 0.29 to 0.62, and operating cash flow declined 102.5% from $9.62M to -$241.
C
Hold
2/15/2017Downgrade
Neogenomics, Inc. (NEO) was downgraded to C- from C on 2/15/2017 due to a decline in the total return index.
Neogenomics, Inc. (NEO) was downgraded to C- from C on 2/15/2017 due to a decline in the total return index.
C
Hold
12/15/2016Upgraded
Neogenomics, Inc. (NEO) was upgraded to C from C- on 12/15/2016 due to a major increase in the total return index and volatility index.
Neogenomics, Inc. (NEO) was upgraded to C from C- on 12/15/2016 due to a major increase in the total return index and volatility index.
C
Hold
11/25/2016Upgraded
Neogenomics, Inc. (NEO) was upgraded to C- from D+ on 11/25/2016 due to an increase in the volatility index, solvency index and total return index.
Neogenomics, Inc. (NEO) was upgraded to C- from D+ on 11/25/2016 due to an increase in the volatility index, solvency index and total return index.
D
Sell
11/9/2016Downgrade
Neogenomics Inc. (NEO) was downgraded to D+ from C- on 11/9/2016 due to a large decline in the total return index, growth index and efficiency index. Net income declined 116.22% from $413 to -$67, EBIT declined 36.39% from $2.19M to $1.4M, and total revenue declined 3.75% from $63.13M to $60.76M.
Neogenomics Inc. (NEO) was downgraded to D+ from C- on 11/9/2016 due to a large decline in the total return index, growth index and efficiency index. Net income declined 116.22% from $413 to -$67, EBIT declined 36.39% from $2.19M to $1.4M, and total revenue declined 3.75% from $63.13M to $60.76M.
C
Hold
8/22/2016Downgrade
Neogenomics Inc. (NEO) was downgraded to C- from C on 8/22/2016 due to a large decline in the total return index and efficiency index.
Neogenomics Inc. (NEO) was downgraded to C- from C on 8/22/2016 due to a large decline in the total return index and efficiency index.
C
Hold
5/27/2016Upgraded
Neogenomics Inc. (NEO) was upgraded to C from C- on 5/27/2016 due to a major increase in the total return index.
Neogenomics Inc. (NEO) was upgraded to C from C- on 5/27/2016 due to a major increase in the total return index.
C
Hold
5/24/2016Upgraded
Neogenomics Inc. (NEO) was upgraded to C- from D+ on 5/24/2016 due to a noticeable increase in the total return index, valuation index and efficiency index. Net income increased 110.52% from -$1.47M to $155.
Neogenomics Inc. (NEO) was upgraded to C- from D+ on 5/24/2016 due to a noticeable increase in the total return index, valuation index and efficiency index. Net income increased 110.52% from -$1.47M to $155.
D
Sell
3/11/2016Downgrade
Neogenomics Inc. (NEO) was downgraded to D+ from C- on 3/11/2016 due to a significant decline in the volatility index and total return index.
Neogenomics Inc. (NEO) was downgraded to D+ from C- on 3/11/2016 due to a significant decline in the volatility index and total return index.
C
Hold
3/7/2016Downgrade
Neogenomics Inc. (NEO) was downgraded to C- from C on 3/7/2016 due to a large decline in the growth index, efficiency index and total return index. Net income declined 28.98% from -$176 to -$125, earnings per share declined from -$0.0029 to -$0.0021, and operating cash flow declined 11.51% from $2.68M to $2.38M.
Neogenomics Inc. (NEO) was downgraded to C- from C on 3/7/2016 due to a large decline in the growth index, efficiency index and total return index. Net income declined 28.98% from -$176 to -$125, earnings per share declined from -$0.0029 to -$0.0021, and operating cash flow declined 11.51% from $2.68M to $2.38M.
C
Hold
11/7/2014Downgrade
Neogenomics Inc. (NEO) was downgraded to C from C+ on 11/7/2014 due to a large decline in the total return index, efficiency index and growth index. Earnings per share declined from $0.0055 to -$0.01, net income declined 206.2% from $274 to -$291, and operating cash flow declined 25.91% from $4.27M to $3.17M.
Neogenomics Inc. (NEO) was downgraded to C from C+ on 11/7/2014 due to a large decline in the total return index, efficiency index and growth index. Earnings per share declined from $0.0055 to -$0.01, net income declined 206.2% from $274 to -$291, and operating cash flow declined 25.91% from $4.27M to $3.17M.
C
Hold
9/26/2014Upgraded
Neogenomics Inc. (NEO) was upgraded to C+ from C on 9/26/2014 due to a major increase in the efficiency index, total return index and valuation index. Net income increased 168.63% from $102 to $274.
Neogenomics Inc. (NEO) was upgraded to C+ from C on 9/26/2014 due to a major increase in the efficiency index, total return index and valuation index. Net income increased 168.63% from $102 to $274.
NASDAQ
03/07/2025 4:00PM Eastern
Quotes delayed
